Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of sacituzumab govitecan plus alpelisib for
treatment of metastatic or locally recurrent HER2-negative breast cancer.